Drug Trial Radar · NCT07313917
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Feb 28, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LP-003 InjectionBiological
s.c. injection, Q12W
Placebo of LP-003Biological
s.c. injection, Q12W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Nasal Polyps Score (NPS) at Week 24Time frame: Week 24
- Change from baseline in Nasal Congestion Score (NCS) at Week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.